Impax Asset Management Group plc Buys Shares of 180,729 Qiagen (NYSE:QGEN)

Impax Asset Management Group plc purchased a new stake in Qiagen (NYSE:QGEN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 180,729 shares of the company’s stock, valued at approximately $8,236,000. Impax Asset Management Group plc owned 0.08% of Qiagen at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of QGEN. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after acquiring an additional 243 shares during the last quarter. CWM LLC lifted its holdings in shares of Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after acquiring an additional 269 shares during the last quarter. Atria Investments Inc lifted its holdings in shares of Qiagen by 6.0% in the 3rd quarter. Atria Investments Inc now owns 7,632 shares of the company’s stock worth $348,000 after acquiring an additional 433 shares during the last quarter. Private Advisor Group LLC increased its stake in shares of Qiagen by 8.0% in the third quarter. Private Advisor Group LLC now owns 6,251 shares of the company’s stock worth $285,000 after buying an additional 461 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $41.28 on Friday. The firm’s 50 day moving average price is $43.85 and its 200-day moving average price is $43.75. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The company has a quick ratio of 1.46, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $9.42 billion, a PE ratio of 105.85, a price-to-earnings-growth ratio of 3.24 and a beta of 0.41.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research note on Thursday, October 17th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Finally, Robert W. Baird boosted their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.88.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.